THIS DOCUMENT IS A CONFIRMING COPY OF THE SCHEDULE 13G FILED
ON FEBRUARY 14, 1997 PURSUANT TO A RULE 201 TEMPORARY HARDSHIP
EXEMPTION.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION STATEMENT PURSUANT TO RULES 13d-1 and 13d-2
UNDER THE SECURITIES EXCHANGE ACT 1934(1)
DIGENE CORPORATION
-------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
-------------------------------------------------------------------------
(Title of Class of Securities)
253752 10 9
-----------------
(CUSIP Number)
Check the following box if a fee is being paid with this Statement. [ ]
(A fee is not required only if the reporting person: (1) has a previous
statement on file reporting beneficial ownership of more than five percent
of the class of securities described in Item 1; and (2) has filed no
amendment subsequent thereto reporting beneficial ownership of five percent
or less of such class. (See Rule 13d-7.)
--------------------
1 The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall
not be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
Page 1
<PAGE>
--------------------- -----------------
CUSIP No. 253752 10 9 13G Page 2 of 5 Pages
--------------------- -----------------
--------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
MUREX DIAGNOSTICS CORPORATION
--------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
--------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------
4 SOURCE OF FUNDS*
WC
--------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(d) or 2(e) [ ]
--------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
--------------------------------------------------------------------------
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:
--------------------------------------------------------------------------
7 SOLE VOTING POWER
736,546
--------------------------------------------------------------------------
8 SHARED VOTING POWER
- 0 -
--------------------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
736,546
--------------------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- 0 -
--------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
736,546
--------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [ ]
--------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
6.5%
--------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT
Page 2
<PAGE>
SCHEDULE 13G
------------
ITEM 1(a). NAME OF ISSUER:
--------------
Digene Corporation (the "Issuer").
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
-----------------------------------------------
9000 Virginia Manor Road
Beltsville, Maryland 20705
ITEM 2(a). NAME OF PERSON FILING:
---------------------
Murex Diagnostics Corporation ("Murex").
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:
------------------------------------
Murex Diagnostics Corporation
Second Floor
Trident House
Bridgetown, St. Michael
Barbados
ITEM 2(c). CITIZENSHIP:
-----------
Murex is a Barbados corporation.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
----------------------------
Common Stock, $.01 par value
ITEM 2(e). CUSIP NUMBER:
------------
253752 10 9
ITEM 3. TYPE OF PERSON:
--------------
Not applicable
ITEM 4. OWNERSHIP.
---------
(a) Amount Beneficially Owned: As of December 31, 1996, Murex
owned 736,546 shares of the
Issuer's Common Stock.
(b) Percent of Class: 6.5%
(c) Number of Shares as to which Murex has:
(i) Sole power to vote or direct the vote:
736,546 shares;
(ii) Shared power to vote or direct the vote:
- 0 - shares;
Page 3
<PAGE>
(iii) Sole power to dispose or to direct the
disposition of:
736,546 shares;
(iv) Shared power to dispose or to direct the
disposition of:
- 0- shares.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
--------------------------------------------
Not applicable.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF
------------------------------------------------
ANOTHER PERSON.
--------------
Not applicable.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY
---------------------------------------------------
WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE
----------------------------------------------------
PARENT HOLDING COMPANY.
----------------------
Not applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE
---------------------------------------------------
GROUP.
-----
Not applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
------------------------------
Not applicable.
Page 4
<PAGE>
ITEM 10. CERTIFICATION.
-------------
By signing below I certify that, to the best of my
knowledge and belief, the securities referred to above were
acquired in the ordinary course of business and were not acquired
for the purpose of and do not have the effect of changing or
influencing the control of the issuer of such securities and were
not acquired in connection with or as a participant in any
transaction having such purpose or effect.
SIGNATURE
---------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and accurate.
Dated: February 13, 1997
MUREX DIAGNOSTICS CORPORATION
/s/ Lynwood S. Bell
----------------------------------
By: Lynwood S. Bell,
Managing Director
